Dr Gillmore has an international reputation in the field of amyloidosis, consolidating the work he performed in this area during his MD and PhD studies. He has published extensively on amyloidosis and continues to do so.
He developed a network of haematologists across the UK who have an interest in treating patients with the commonest form of amyloidosis, AL type, which he harnessed to undertake the first randomized controlled trial of treatment in this most serious disease. He has worked closely with the UK Myeloma Forum and leaders in haematological cancer to achieve this difficult goal. He has been involved with the foundation of patient support group and is chair and principal author of the British Guidelines on the management of AL Amyloidosis, published in 2013.
He highlighted for the first time in a systematic fashion, the relationship between the abundance of amyloid fibril precursor proteins, the course of amyloid deposits and clinical outcome in a number of different forms of amyloidosis. His widely cited seminal paper published in the Lancet (2001) had a major impact on management of AA amyloidosis and amyloidosis generally.
He has been responsible for and/or involved in many of the advances in therapy for systemic AL amyloidosis including novel chemotherapy regimens (CTD, bortezomib, and stem cell transplantation) and transplantation (cardiac and renal) over recent years. The survival of systemic AL amyloidosis has steadily improved, in part, as a result of such advances. He has also made critical contributions to evaluation and publication of the first recipients of orthotopic liver transplants as curative ‘surgical gene therapy’ in a number of hereditary forms of amyloidosis.